Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities

Hepatocellular carcinoma (HCC) remains a major health problem worldwide with a continuous increasing prevalence. Despite the introduction of targeted therapies like the multi-kinase inhibitor sorafenib, treatment outcomes are not encouraging. The prognosis of advanced HCC is still dismal, underlying...

Descripción completa

Detalles Bibliográficos
Autores principales: Garmpis, Nikolaos, Damaskos, Christos, Garmpi, Anna, Georgakopoulou, Vasiliki E., Sarantis, Panagiotis, Antoniou, Efstathios A., Karamouzis, Michalis V., Nonni, Afroditi, Schizas, Dimitrios, Diamantis, Evangelos, Koustas, Evangelos, Farmaki, Paraskevi, Syllaios, Athanasios, Patsouras, Alexandros, Kontzoglou, Konstantinos, Trakas, Nikolaos, Dimitroulis, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004277/
https://www.ncbi.nlm.nih.gov/pubmed/33809844
http://dx.doi.org/10.3390/jpm11030223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004277/
https://www.ncbi.nlm.nih.gov/pubmed/33809844
http://dx.doi.org/10.3390/jpm11030223

Ejemplares similares